Theravance Biopharma (TBPH) Current Taxes (2014 - 2026)

Theravance Biopharma (TBPH) has reported Current Taxes for 4 consecutive years, with $5.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Taxes fell 9.67% year-over-year to $5.3 million; the TTM figure through Mar 2026 stood at $5.3 million (down 9.67% YoY), while the FY2025 annual figure was $5.3 million, down 9.67% from the prior year.
• Current Taxes held at $5.3 million in Q1 2026 per TBPH's latest filing, from $5.3 million in the prior quarter.
• Across five years, Current Taxes topped out at $26.7 million in Q2 2025 and bottomed at $4.1 million in Q3 2025.
• Historically, Current Taxes has averaged $8.8 million across 3 years, with a median of $5.6 million in 2024.
• On a YoY basis, Current Taxes climbed as much as 9.67% in 2025 and fell as far as 9.67% in 2025.
• Theravance Biopharma's Current Taxes stood at $5.9 million in 2024, then fell by 9.67% to $5.3 million in 2025, then changed by 0.0% to $5.3 million in 2026.
• Business Quant data shows TBPH's Current Taxes at $5.3 million in Q1 2026, $5.3 million in Q4 2025, and $4.1 million in Q3 2025.